Israel News App

ESMO 2025: Multi Cycle Dosimetry of the Albumin Binding PSMA Ligand [¹⁷⁷Lu]Ludotadipep in Metastatic Castration Resistant Prostate Cancer: Phase II Trial Results – UroToday

Written by

admin

in

  1. ESMO 2025: Multi Cycle Dosimetry of the Albumin Binding PSMA Ligand [¹⁷⁷Lu]Ludotadipep in Metastatic Castration Resistant Prostate Cancer: Phase II Trial Results  UroToday
  2. ASTRO: New therapy delays progression of recurrent prostate cancer  

Continue Reading